ID   CRO-AP2
AC   CVCL_1147
SY   CRO-AP/2; CROAP2; AP2
DR   BTO; BTO:0002724
DR   CLO; CLO_0002617
DR   EFO; EFO_0002145
DR   CLDB; cl3486
DR   ArrayExpress; E-MTAB-3610
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   BioSample; SAMN03473560
DR   CCLE; CROAP2_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR   Cell_Model_Passport; SIDM00952
DR   ChEMBL-Cells; CHEMBL3308254
DR   ChEMBL-Targets; CHEMBL2366080
DR   Cosmic; 906807
DR   Cosmic-CLP; 906807
DR   DepMap; ACH-002220
DR   DSMZ; ACC-48
DR   GDSC; 906807
DR   GEO; GSM634729
DR   GEO; GSM1669709
DR   IGRhCellID; CROAP2
DR   Wikidata; Q54814506
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=9389573;
RX   PubMed=10784388;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=20454443;
RX   PubMed=21685375;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=31160637;
WW   http://www.cells-talk.com/index.php/page/copelibrary?key=CRO-AP%2f2
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Part of: LL-100 blood cancer cell line panel.
CC   Doubling time: ~20-40 hours (DSMZ).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Transformant: NCBI_TaxID; 37296; Human herpesvirus 8 (HHV-8/KSHV).
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=0.25%; Native American=0.15%; East Asian, North=0.73%; East Asian, South=0.29%; South Asian=5.13%; European, North=44.53%; European, South=48.9% (PubMed=30894373).
CC   Derived from sampling site: Pleural effusion.
ST   Source(s): Cosmic-CLP; DSMZ
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 11
ST   D16S539: 11
ST   D5S818: 12
ST   D7S820: 10,11
ST   TH01: 6,8
ST   TPOX: 10,11
ST   vWA: 17,18
DI   NCIt; C6915; Primary effusion lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
AG   49Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-07-19; Version: 22
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=9389573; DOI=10.1002/(SICI)1097-0215(19971114)73:4<562::AID-IJC18>3.0.CO;2-B;
RA   Carbone A., Cilia A.M., Gloghini A., Canzonieri V., Pastore C.,
RA   Todesco M., Cozzi M., Perin T., Volpe R., Pinto A., Gaidano G.;
RT   "Establishment of HHV-8-positive and HHV-8-negative lymphoma cell
RT   lines from primary lymphomatous effusions.";
RL   Int. J. Cancer 73:562-569(1997).
//
RX   PubMed=10784388; DOI=10.3109/10428190009148391;
RA   Carbone A., Cilia A.M., Gloghini A., Capello D., Perin T.,
RA   Bontempo D., Canzonieri V., Tirelli U., Volpe R., Gaidano G.;
RT   "Primary effusion lymphoma cell lines harbouring human herpesvirus
RT   type-8.";
RL   Leuk. Lymphoma 36:447-456(2000).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=20454443; DOI=10.1155/2010/904767;
RA   Uphoff C.C., Denkmann S.A., Steube K.G., Drexler H.G.;
RT   "Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in human
RT   and other primate cell lines.";
RL   J. Biomed. Biotechnol. 2010:904767-904767(2010).
//
RX   PubMed=21685375; DOI=10.1182/blood-2010-12-323659;
RA   Roy D., Sin S.-H., Damania B., Dittmer D.P.;
RT   "Tumor suppressor genes FHIT and WWOX are deleted in primary effusion
RT   lymphoma (PEL) cell lines.";
RL   Blood 118:E32-E39(2011).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//